Company news
Quantum Cyber N.V. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 15, 2023
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
November 14, 2023
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
November 12, 2023
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
November 8, 2023
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
November 6, 2023
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
October 30, 2023
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
October 25, 2023
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
October 17, 2023
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
October 10, 2023
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
October 3, 2023
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
September 12, 2023
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
September 4, 2023
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
August 21, 2023
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
August 14, 2023
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
July 31, 2023
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
July 17, 2023
Mainz Biomed Secures up to $50M in New Funding
June 28, 2023
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
June 19, 2023
Mainz Biomed Expands Commercial Footprint into Poland
May 30, 2023
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
May 23, 2023
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
May 9, 2023
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
May 2, 2023
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
April 26, 2023
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
April 25, 2023
Mainz Biomed Provides Full Year 2022 Financial Results
April 9, 2023
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
April 3, 2023
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
March 28, 2023
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
March 14, 2023
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
February 20, 2023
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
February 14, 2023
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
January 17, 2023
Mainz Biomed Provides Year-End 2022 Corporate Review
January 2, 2023
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
December 19, 2022
Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
December 5, 2022
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
November 28, 2022
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
November 14, 2022
Mainz Biomed Provides Third Quarter 2022 Update
November 1, 2022
Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
September 27, 2022
Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board
September 19, 2022
Mainz Biomed Reports First Half 2022 Financial Results
September 6, 2022
Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates
August 15, 2022
Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development
August 2, 2022
Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board
July 18, 2022
Mainz Biomed Today to Provide Corporate Update for First Half of 2022
July 11, 2022
Mainz Biomed Provides Corporate Update for First Half of 2022
July 4, 2022
Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
June 27, 2022
Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission
June 13, 2022
Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance
May 31, 2022
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
May 18, 2022
Decks
- Investor Presentation (September 2026)
Investor deck · 14 slides · Sep 25, 2026
- Investor Presentation (July 2026)
Investor deck · 21 slides · Jul 24, 2026
- Investor Presentation (June 2026)
Investor deck · 19 slides · Jun 3, 2026